Knowing how to live with rheumathoid arthritis or ankylosing spondilytis during pregnancy
Keywords:
rheumatoid arthritis, ankylosing spondylitis, drugs, pregnancyAbstract
Rheumathoid arthritis and ankylosing spondilytis are diseases
that strike young women that eventually demonstrate the desire
of getting pregnant. The doctor must be prepared to answer all
questions, pointing out the advantages of planned pregnancy.
The main goal, by achieving the strong collaboration between the
obstetrician and the internist or rheumatologist, is to maintain the
illness inactive, with the safest drugs for the mother and the fetus.
Nothing can stop a woman with RA or AS from being a mother.
In general, one can say pregnancy is a period of immunologic
tolerance, being even possible to wait for these diseases to get better.
Downloads
References
Christina D Chambers, Zuehre N Tutuncu, Diana Johnson, Kenneth L Jones: Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Research & Therapy 2006, 8:225.
Christina Chambers, Gideon Koren, Zuhre n Tutuncu, Diana Johnson, Keneth L Jones: Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Canadian Family Physician 2007; 53: 409-412.
Bonnie L Bermas: Rheumatoid arthritis and pregnancy.www.UpToDate.com2007.
Benjamin Bar Oz, Richard Hackman, Tom Einarson, Gideon Koren: Pregnancy outcome after cyclosporine therapy during pregnancy: A meta-analysis. Transplantation 2001; 71(8): 1051-1055.
Vishal R Tandon, Sudhaa Sharma, Annil Mahajan, Vijay Kahajuria, Ajay Kumar: Pregnancy and Rheumatoid Arthritis. Indian J Med Sci 2006;
(8):334-344.
M Ostensen, L Fuhrer, R Mathieu, MSeitz, P M Villiger: A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 2004;63:1212-1217.
Namieta M janssen, Marcia S Genta: The effects of immunosupressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000; 160: 610-619.
P Saar, W Hermann, U Muller-Ladner:Connective tissue diseases and pregnancy. Rheumatology 2006;45:30-32.
Fokaline Vroom, Hermien Walle, Mart Van de Laar, Jacobus Brouwers, Lolkje Jong-van den Berg: Disease-Modifying Antirheumatic Drugs in Pregnancy. Drug Safety 2006:29(10):845-863.
A J Kinder, J Edwards, A Samanta, F Nichol: Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate. Rheumatology 2004;43:1195-1196.
Bénédicte Lewden,Thierry Vial,Elisabeth Elefant, Agnés Nelva, Patrick Carlier, Jacqes Descotes: Low dose methotrexate in the first trimester of pregnancy: results of a French Collaborative Study. The Journal of Rheumatology
;31(12): 2360-2364.
Monika Ostensen, Helge Hartmann, Kjell Salvesen: Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. The Journal of Rheumatology 2000;27(8): 1872-1875.
Jeffry A Katz, Christian Antoni, Gregory F Keenan, Deirdre E Smith, Stephen J. Jacobs, Gary R Lichtenstein: Outcome of pregnancy in women
receiving infliximab for the treatment of Crohn’s Disease and Rheumatoid Arthritis. Am J Gastroenterol 2004;99:2385-2392.
Chakravarty E F, Sanchez Yamamoto, Bush T M:Disease Modifying antirheumatic drugs in women with Rheumatoid Arthritis of childbearing age:a survey of pratice pattern and frequency outcomes. J Rheumatol 2003;30:241-246.
Josef S Smolen, Daniel Aletaha, Michael H Weisman, Paul Emery: New Therapies for treatment of rheumatoid arthritis.www.thelancet.com Published online June 13, 2007.
Kimby E, Sverrisdottir A, Ellinder G: Safety of rituximab therapy during the first trimester of pregnancy:a case history. Eur J Haematol 2004;72(4):292-295.
Ojeda-Uribe M, Guilliot C, Jung G, Drenou B, Brunot A: Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006;26(4):252-255.
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
